[HTML] nih.gov

[HTML][HTML] Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

C Mecca, V Bertaglia, S Novello - Translational Cancer Research, 2019 - ncbi.nlm.nih.gov
VEGFRs 1/2/3. Its antitumor efficacy was demonstrated in several human tumor xenograft
models (13). In clinical development this molecule has been evaluated within a phase II …
相关文章

Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

C Mecca, V Bertaglia, S Novello - Translational Cancer Research, 2019 - europepmc.org
VEGFRs 1/2/3. Its antitumor efficacy was demonstrated in several human tumor xenograft
models (13). In clinical development this molecule has been evaluated within a phase II …
[HTML] amegroups.org

[HTML][HTML] Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

C Mecca, V Bertaglia, S Novello - Translational Cancer Research, 2019 - tcr.amegroups.org
Lung cancer is the leading cause of cancer-related deaths worldwide. Among all the
different types, non-small cell lung cancer (NSCLC) accounts for 80–85% and most patients …
[PDF] amegroups.cn

[PDF][PDF] Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

C Mecca, V Bertaglia, S Novello - 2019 - cdn.amegroups.cn
VEGFRs 1/2/3. Its antitumor efficacy was demonstrated in several human tumor xenograft
models (13). In clinical development this molecule has been evaluated within a phase II …

[引用][C] Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

C Mecca, V Bertaglia, S Novello - Translational cancer …, 2019 - pubmed.ncbi.nlm.nih.gov

[引用][C] Third line scenario in advanced non-small cell lung cancer: Is the anti-angiogenetic strategy the only actor up to now?

C Mecca, V Bertaglia, S Novello - TRANSLATIONAL CANCER …, 2019 - iris.unito.it
Third line scenario in advanced non-small cell lung cancer: Is the anti-angiogenetic strategy
the only actor up to now? IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo …

Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

C Mecca, V Bertaglia, S Novello - Translational Cancer Research, 2019 - tcr.amegroups.org
Lung cancer is the leading cause of cancer-related deaths worldwide. Among all the
different types, non-small cell lung cancer (NSCLC) accounts for 80–85% and most patients …